“Multicenter, randomized, double-blind, parallel-group, placebo-controlled study of mepolizumab 100 mg SC as adjunctive treatment in participants with COPD, experiencing frequent exacerbations and characterized by eosinophil levels
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: GLAXOSMITHKLINE RESEARCH DEVELOPMENT LTD
- Phase: III
- Execution start: 26/07/2022
- End of execution: 31/07/2024
- PI: BERNARDINO ALCAZAR NAVARRETE